Britain's mid-cap manufacturers spend their lives at the mercy of the industrial cycle: order books swell when factories, aircraft makers and construction firms are busy, and thin out when they are not. Three FTSE 250 names show three very different responses to that reality in 2026. Coats Group (LSE:COA) is buying its way into faster-growing niches. Bodycote (LSE:BOY) has agreed to leave the public market altogether. Morgan Advanced Materials (LSE:MGAM) is selling Assets and cutting Debt while it waits for Demand to turn. Together they offer a snapshot of how industrial businesses cope when growth is hard to come by.

Coats Group (LSE:COA)

Coats is the world's leading industrial thread and structural-components maker, supplying the apparel and footwear industries and a growing performance-materials arm. Its half-year results on 28 July 2026 (six months to 30 June) showed Revenue of $837 million, up 1% organically, but adjusted operating profit of $166 million, up 19%, at a 19.8% margin. The Interim Dividend rose 5% to 1.05 cents. Net debt stood at $842 million, equivalent to 2.3 times earnings.

The standout strategic move is the $770 million Acquisition of OrthoLite, the US premium-insole maker, agreed in July 2025 and completed in the fourth quarter. The deal, struck at about ten times EBITDA before synergies, was part-funded by a placing that raised around £250 million plus a retail offer and new debt, and management expects roughly $20 million of cost synergies by 2028. In the first half OrthoLite's revenue slipped against strong comparators and temporary capacity constraints, though the company expects it to return to growth in the second half.

End markets were mixed: apparel grew 1% organically and footwear was broadly flat but returning to growth in the second quarter. Coats maintained full-year guidance, pointing to only modest market declines in the second half and around $15 million of incremental cost actions. Its medium-term ambitions include annual revenue growth above 5%, roughly $1 billion of cumulative free Cash Flow over five years and net Leverage back to about 2.0 times by year-end. The integration of OrthoLite and the pace of debt reduction are what investors will follow.

Bodycote (LSE:BOY)

Bodycote, the Macclesfield-based world leader in heat treatment and specialist thermal processing, is the clearest sign of how the Manufacturing cycle is playing out in the boardroom rather than the order book. On 1 September 2026 the company announced a recommended cash acquisition by Vulcan Alpha Bidco, a vehicle backed by the US private-equity firm Veritas Capital.

The terms value Bodycote at 940 pence per share, made up of 932.8 pence in cash plus a 7.2 pence interim dividend, for a total of about £1.65 billion on a fully diluted basis. That represents a premium of roughly 37.5% to the three-month volume-weighted average price to 21 May 2026. The board recommended the offer unanimously, and it is structured as a court-sanctioned scheme of arrangement, expected to complete in the first quarter of 2027, subject to Shareholder and regulatory approvals. A rival proposal from CVC, pitched at 915 pence, did not progress to a firm offer. The flurry of Takeover Panel disclosure forms filed in mid-September reflects an active Offer Period rather than routine trading.

Bodycote serves aerospace, defence, automotive and general industrial customers across some 22 countries, businesses that are highly sensitive to the industrial cycle and to aerospace build rates. For now it remains a FTSE 250 constituent, but if the scheme completes as planned it will leave the public market and drop out of the index. Shareholders' immediate attention is therefore on the scheme timetable and the shareholder votes rather than on quarterly trading.

Morgan Advanced Materials (LSE:MGAM)

Morgan Advanced Materials makes advanced ceramics and carbon-based products for aerospace, defence, energy, semiconductor and industrial customers. Its response to a subdued cycle has been to simplify the portfolio and pay down borrowings. Half-year results on 6 August 2026 (six months to 30 June) showed revenue of £518 million, up 4.8% organically in constant currency, with adjusted operating profit of £57.8 million at an 11.2% margin. The interim dividend was held at 5.4 pence, net debt was £253 million, or 2.0 times EBITDA, and adjusted Earnings per share came in at 10.7 pence.

The divisional picture reflected where industrial demand is and is not. Technical Ceramics grew 7.8% in constant currency, helped by aerospace and defence ceramic cores and industrial gas turbines, and improved its Margin by 130 basis points to 13%. Performance Carbon was flatter once a take-or-pay payment was stripped out, with energy strength offsetting weaker body-armour and industrial demand. Thermal Products returned to modest growth of 2.5%, supported by Asia and North America even as European industrial markets stayed soft. Management reiterated a 2028 target of a 12% adjusted operating margin.

On 28 August 2026 the group sold its roughly 15% stake in Foseco India for gross proceeds of about 6,530 million rupees, or net proceeds of around £53 million, earmarked for debt reduction. Those shares had come as partial consideration for the earlier disposal of its Molten Metal Systems Business to Vesuvius, completed in November 2025. Morgan expects leverage of about 1.7 times by the end of FY2026. Whether the aerospace and semiconductor recovery gathers pace is the swing Factor for the shares.

Why These Three Stocks Matter

The trio shows the range of strategies open to industrial companies in a slow cycle. Coats is consolidating and moving up the value chain through acquisition; Bodycote's owners have concluded that private ownership offers a better route than public markets; Morgan is streamlining and deleveraging while it waits. Each carries cyclical risk, exposure to aerospace, defence and general industry, and each is managing a Balance Sheet with an eye on interest costs.

What to Watch Next

For Coats, the OrthoLite integration and the return to leverage of 2.0 times are the near-term markers. For Bodycote, everything now hinges on the scheme vote and the expected 2027 completion. For Morgan, the pace of debt reduction and any pick-up in aerospace and semiconductor demand will set the tone. The broader signal is that, when organic growth is scarce, portfolio decisions and balance-sheet discipline matter as much as the state of the order book.